Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00817765
Other study ID # UMCN-AKF 08.03
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 2009
Est. completion date October 2009

Study information

Verified date November 2020
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the influence of posaconazole on unboosted fosamprenavir pharmacokinetics, and vice versa, in healthy volunteers.A second objective is to determine the safety of combined use of fosamprenavir with posaconazole in healthy volunteers.


Description:

Infections with fungi and yeast frequently occur in patients infected with the human immunodeficiency virus type 1 (HIV-1). Fosamprenavir is a PI that is used to treat HIV-infection in combination with ritonavir. Once hydrolyzed to amprenavir, this substance is a substrate for CYP3A4. Ritonavir is an extremely potent inhibitor of CYP3A4 and serves as a booster of the pharmacokinetics of amprenavir. Posaconazole is a very potent CYP3A4 inhibitor and therefore might enhance amprenavir pharmacokinetics in a similar way as ritonavir. The current study is designed to test this hypothesis. When there is an indication for antifungal therapy in an HIV-infected patient, temporal replacement of ritonavir by posaconazole would be an attractive option for combined treatment of HIV and fungal infection.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date October 2009
Est. primary completion date July 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Subject is at least 18 and not older than 55 years of age on the day of the first dosing. - Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to the first dosing. - Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included. - Subject is able and willing to sign the Informed Consent Form prior to screening evaluations. - Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry, haematology and urinalysis testing within 4 weeks prior to the first dose. - Subject has a normal blood pressure and pulse rate, according to the Investigator's judgement. Exclusion Criteria: - Documented history of sensitivity/idiosyncrasy to medicinal products or excipients. - Positive HIV test. - Positive hepatitis B or C test. - Pregnant female (as confirmed by an HCG test performed less than 4 weeks before the first dose) or breast-feeding female. - Therapy with any drug (for two weeks preceding dosing), except for paracetamol. - Subjects with an ECG with QTc interval greater than 450 ms for men, and greater than 470 ms for women at screening. - Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), gastro-intestinal disorders, renal and hepatic disorders, hormonal disorders (especially diabetes mellitus), coagulation disorders. - Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion. - History of or current abuse of drugs, alcohol or solvents. - Inability to understand the nature and extent of the trial and the procedures required. - Participation in a drug trial within 60 days prior to the first dose. - Donation of blood within 60 days prior to the first dose. - Febrile illness within 3 days before the first dose

Study Design


Intervention

Drug:
Posaconazole
Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
Fosamprenavir
fosamprenavir tablet 700mg; 1 tablet BID for 10 days
Ritonavir
Ritonavir 100mg capsule; 1 capsule BID for 10 days

Locations

Country Name City State
Netherlands Radboud University Nijmegen Medical Centre Nijmegen Gelderland

Sponsors (2)

Lead Sponsor Collaborator
Radboud University GlaxoSmithKline

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Brüggemann RJ, van Luin M, Colbers EP, van den Dungen MW, Pharo C, Schouwenberg BJ, Burger DM. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J Antimicrob Chemother. 2010 Oct;65(10):2188-94. doi: 10.1 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma concentrations of amprenavir and posaconazole predose and at 1, 2, 3, 4, 5, 6, 7, 8, 10 and 12 hours after dosing on Study Days 10, 38 and 66. Predose on study days 1, 3, 5, 8, 29, 31, 33, 36, 57, 59, 61, and 64.
Secondary Adverse events (safety) due to concomitant use of fosamprenavir and posaconazole period of interaction treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Active, not recruiting NCT02663856 - My Smart Age With HIV: Smartphone Self-assessment of Frailty
Completed NCT02921516 - Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings N/A
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Completed NCT02846402 - Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda N/A
Completed NCT02659306 - Metformin Immunotherapy in HIV Infection Phase 1
Completed NCT02663869 - Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
Completed NCT02564341 - Targeting Effective Analgesia in Clinics for HIV - Intervention N/A
Active, not recruiting NCT02302950 - A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas N/A
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Completed NCT02269605 - Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment Phase 1
Completed NCT01830595 - Lactoferrin Treatment in HIV Patients Phase 2
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Phase 2
Completed NCT02118168 - Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002 N/A
Completed NCT02525146 - Birmingham Access to Care Study N/A
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT02527135 - Text Messaging to Improve HIV Testing Among Young Women in Kenya N/A
Active, not recruiting NCT02602418 - Neural Correlates of Working Memory Training for HIV Patients N/A
Completed NCT01680094 - Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART Phase 1/Phase 2